Studies include Alpha, Beta, Gamma, Delta, Epsilon and Iota and it maintains antibodies for six months after the second dose
The company is eligible for 12 months exclusivity from launch
A new market study published by Global Industry Analysts (GIA), released its report titled, ``Healthcare Supply Chain Management—Global Market Trajectory & Analytics.’’ We present excerpts from the report
If approved it will bring a second source of MMR vaccine to the US market
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Company working on COVID vaccine INO 4800
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
The transaction is expected to close in the Q4FY22
Subscribe To Our Newsletter & Stay Updated
